Beyond the Variant: Interpreting Genetic Diseases in the AI Era - Episode 3 Ehlers-Danlos Syndrome (EDS)

Beyond the Variant: Interpreting Genetic Diseases in the AI Era – Episode 3 Ehlers-Danlos Syndrome (EDS)

โ€”

์ œ๊ณต

์•ˆ

๐Ÿ“Œ Series Introduction

์ด ์‹œ๋ฆฌ์ฆˆ๋Š” AI ๊ธฐ๋ฐ˜ ์œ ์ „๋ณ€์ด ํŒ๋… ๋„๊ตฌ๊ฐ€ ๋ณดํŽธํ™”๋œ ์‹œ๋Œ€์—, ์ž๋™ํ™”๋œ ์šฐ์„ ์ˆœ์œ„ํ™” ์ดํ›„ ํŒ๋…์ž๊ฐ€ ์‹ค์ œ๋กœ ๋ฌด์—‡์„ ์ดํ•ดํ•˜๊ณ  ์–ด๋–ป๊ฒŒ ํŒ๋‹จํ•ด์•ผ ํ•˜๋Š”์ง€์— ์ดˆ์ ์„ ๋งž์ถฅ๋‹ˆ๋‹ค.

๊ฐ ํŽธ์—์„œ๋Š” ํ•˜๋‚˜์˜ ์งˆํ™˜๊ตฐ์„ ์ค‘์‹ฌ์œผ๋กœ, ์œ ์ „์  ๊ธฐ์ „๊ณผ ์ž„์ƒ ์ŠคํŽ™ํŠธ๋Ÿผ์„ ํ•จ๊ป˜ ์‚ดํŽด๋ณด๋ฉฐ ๋ณ€์ด๋ฅผ โ€œ์ฐพ๋Š” ๊ฒƒโ€์„ ๋„˜์–ด โ€œ์„ค๋ช…ํ•˜๊ณ  ํ•ด์„ํ•˜๋Š”โ€ ๋ฐ ํ•„์š”ํ•œ ๊ด€์ ์„ ๊ณต์œ ํ•˜๊ณ ์ž ํ•ฉ๋‹ˆ๋‹ค.

Ehlers-Danlos syndrome(EDS)์€ ์ฝœ๋ผ๊ฒ๊ณผ ์„ธํฌ์™ธ๊ธฐ์งˆ(ECM)์˜ ์ด์ƒ์œผ๋กœ ๋ฐœ์ƒํ•˜๋Š” ์œ ์ „์„ฑ ๊ฒฐํ•ฉ์กฐ์ง ์งˆํ™˜๊ตฐ์ž…๋‹ˆ๋‹ค.


ํ”ผ๋ถ€, ๊ด€์ ˆ, ํ˜ˆ๊ด€, ๊ทผ๊ณจ๊ฒฉ๊ณ„ ๋“ฑ ๋‹ค์–‘ํ•œ ์กฐ์ง์—์„œ ๊ตฌ์กฐ์  ์ทจ์•ฝ์„ฑ์ด ๋‚˜ํƒ€๋‚˜๋ฉฐ, ์งˆํ™˜์˜ ํ‘œํ˜„ํ˜•๋„ ๋งค์šฐ ๋‹ค์–‘ํ•˜๊ฒŒ ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒƒ์ด ํŠน์ง•์ž…๋‹ˆ๋‹ค.

์ด๋ฒˆ Episode 3์—์„œ๋Š”ย EDS์˜ ์ •์˜, ๋ถ„๋ฅ˜, ์›์ธ ์œ ์ „์ž, ๋ถ„์ž์  ๋ณ‘ํƒœ์ƒ๋ฆฌ, ๊ทธ๋ฆฌ๊ณ  ์ž„์ƒ ์ง„๋‹จ ๊ธฐ์ค€๊นŒ์ง€ ์ฒด๊ณ„์ ์œผ๋กœ ์ •๋ฆฌํ•ฉ๋‹ˆ๋‹ค.


Episode 3 โ€”ย Ehlers-Danlos Syndrome (EDS)ย ๊ด€๋ จ ์งˆํ™˜

๐Ÿ” Ehlers-Danlos Syndrome์ด๋ž€?

Ehlers-Danlos syndrome์€ ๊ฒฐํ•ฉ์กฐ์ง(connective tissue)์˜ ๊ตฌ์กฐ์  ๊ฒฐํ•จ์œผ๋กœ ๋ฐœ์ƒํ•˜๋Š” ํฌ๊ท€ ์œ ์ „ ์งˆํ™˜๊ตฐ์ž…๋‹ˆ๋‹ค.

์งˆํ™˜๋ช…์€ ๋‘ ๋ช…์˜ ํ”ผ๋ถ€๊ณผ ์˜์‚ฌ์—์„œ ์œ ๋ž˜ํ–ˆ์Šต๋‹ˆ๋‹ค.

  • Edvard Ehlers
  • Henri-Alexandre Danlos

์ด ์งˆํ™˜์˜ ํ•ต์‹ฌ ํŠน์ง•์€ ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค.

์ฃผ์š” ์ž„์ƒ ํŠน์ง•

  • ๊ด€์ ˆ ๊ณผ์šด๋™์„ฑ (Joint hypermobility)
  • ํ”ผ๋ถ€ ๊ณผ์‹ ์ „ (Skin hyperextensibility)
  • ๋น„์ •์ƒ์ ์ธ ์ƒ์ฒ˜ ์น˜์œ 
  • ์‰ฝ๊ฒŒ ์ƒ๊ธฐ๋Š” ๋ฉ (Easy bruising)

๊ฒฐํ•ฉ์กฐ์ง์€ ์ธ์ฒด ๋Œ€๋ถ€๋ถ„์˜ ์žฅ๊ธฐ์—์„œ ๊ตฌ์กฐ์  ์ง€์ง€ ์—ญํ• ์„ ํ•˜๊ธฐ ๋•Œ๋ฌธ์—, EDS๋Š” ๋‹จ์ˆœ ํ”ผ๋ถ€ ์งˆํ™˜์ด ์•„๋‹ˆ๋ผ ์ „์‹ ์ ์ธ(multisystem) ๊ฒฐํ•ฉ์กฐ์ง ์งˆํ™˜์ž…๋‹ˆ๋‹ค.


๐Ÿงฌ Ehlers-Danlos Syndrome ๋ถ„๋ฅ˜

ํ˜„์žฌ ๊ตญ์ œ์ ์œผ๋กœ 14๊ฐœ์˜ EDS subtype์ด ์ •์˜๋˜์–ด ์žˆ์Šต๋‹ˆ๋‹ค.

๋Œ€ํ‘œ์ ์ธ ์œ ํ˜•์€ ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค.

  • Classical EDS (cEDS)
  • Vascular EDS (vEDS)
  • Kyphoscoliotic EDS (kEDS)
  • Myopathic EDS (mEDS)
  • Periodontal EDS (pEDS)

์ด ์ค‘ 13๊ฐœ subtype์€ ์œ ์ „์ž ์›์ธ์ด ๋ฐํ˜€์ ธ ์žˆ์œผ๋ฉฐ,
Hypermobile EDS (hEDS)๋งŒ์ด ์•„์ง ๋ถ„์ž์  ์›์ธ์ด ๋ช…ํ™•ํžˆ ๋ฐํ˜€์ง€์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

EDS ๋ฐœ์ƒ๋ฅ 

EDS subtype๋ณ„ ๋ฐœ์ƒ๋ฅ ์˜ ์˜ˆ์‹œ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค

  • Classical EDS: ์•ฝ 1 / 20,000
  • Vascular EDS: ์•ฝ 1 / 50,000 โ€“ 1 / 200,000

์ผ๋ถ€ subtype์€ ๋งค์šฐ ๋“œ๋ฌธ ํฌ๊ท€์งˆํ™˜์— ํ•ด๋‹นํ•ฉ๋‹ˆ๋‹ค.


๐Ÿง EDS ์›์ธ: ์–ด๋–ค ์œ ์ „์ž ๋ณ€์ด๊ฐ€ ๋ฐœ์ƒํ• ๊นŒ?

ํ˜„์žฌ๊นŒ์ง€ 20๊ฐœ์˜ ์œ ์ „์ž๊ฐ€ EDS์™€ ๊ด€๋ จ๋˜์–ด ์žˆ์Šต๋‹ˆ๋‹ค.

๋Œ€ํ‘œ์ ์ธ ์œ ์ „์ž๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค.

COL5A1COL5A2COL1A1COL3A1
COL1A2ADAMTS2PLOD1FKBP14
TNXBCOL12A1CHST14DSE
B4GALT7B3GALT6SLC39A13ZNF469
PRDM5C1RC1SAEBP1

EDS์˜ ์œ ์ „ ๋ฐฉ์‹์€ ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค.

  • ์ƒ์—ผ์ƒ‰์ฒด ์šฐ์„ฑ (Autosomal dominant)
  • ์ƒ์—ผ์ƒ‰์ฒด ์—ด์„ฑ (Autosomal recessive)

์ด ์œ ์ „์ž๋“ค์€ ๊ธฐ๋Šฅ์ ์œผ๋กœ ํฌ๊ฒŒ ์„ธ ๊ฐ€์ง€ ๋ฒ”์ฃผ๋กœ ๋‚˜๋‰ฉ๋‹ˆ๋‹ค.

1. Fibrillar collagen ๋‹จ๋ฐฑ์งˆ

  • COL1A1
  • COL3A1
  • COL5A1
  • COL5A2

2. Collagen processing ํšจ์†Œ

  • ADAMTS2
  • PLOD1
  • FKBP14

3. ECM ๋ฐ proteoglycan ๊ด€๋ จ ๋‹จ๋ฐฑ์งˆ

  • TNXB
  • B4GALT7
  • CHST14
  • DSE

์ด๋Ÿฌํ•œ ์œ ์ „์ž ๋ณ€์ด๋Š” ๋ชจ๋‘ ์ฝœ๋ผ๊ฒ ๊ตฌ์กฐ ๋˜๋Š” ์„ธํฌ์™ธ๊ธฐ์งˆ(ECM)์˜ ์•ˆ์ •์„ฑ์— ์˜ํ–ฅ์„ ๋ฏธ์นฉ๋‹ˆ๋‹ค.


๐Ÿ“Œ ์ฝœ๋ผ๊ฒ ๊ตฌ์กฐ์™€ EDS์˜ ๋ถ„์ž์  ๊ธฐ์ „

EDS๋ฅผ ์ดํ•ดํ•˜๋ ค๋ฉด ๋จผ์ € ์ฝœ๋ผ๊ฒ์˜ ๊ธฐ๋ณธ ๊ตฌ์กฐ๋ฅผ ์ดํ•ดํ•ด์•ผ ํ•ฉ๋‹ˆ๋‹ค.

์ฝœ๋ผ๊ฒ triple helix ๊ตฌ์กฐ

์ฝœ๋ผ๊ฒ์€ ์„ธํฌ ๋‚ด์—์„œ ํ”„๋กœ์ฝœ๋ผ๊ฒ(procollagen) ํ˜•ํƒœ๋กœ ํ•ฉ์„ฑ๋œ ํ›„, proteolytic cleavage๋ฅผ ๊ฑฐ์ณ ์„ฑ์ˆ™ํ•œ ์ฝœ๋ผ๊ฒ(mature collagen)์œผ๋กœ ์ „ํ™˜๋ฉ๋‹ˆ๋‹ค.
ํ”„๋กœ์ฝœ๋ผ๊ฒ์€ ์„ธ ๊ฐœ์˜ ํด๋ฆฌํŽฉํƒ€์ด๋“œ ฮฑ-chain์œผ๋กœ ๊ตฌ์„ฑ๋˜๋ฉฐ, ์ด๋“ค์ด ๊ฒฐํ•ฉํ•˜์—ฌ ์‚ผ์ค‘ ๋‚˜์„ (triple helix) ๊ตฌ์กฐ๋ฅผ ํ˜•์„ฑํ•ฉ๋‹ˆ๋‹ค.

์ด ๊ตฌ์กฐ๋Š” ๋™์ผํ•œ ์‚ฌ์Šฌ๋กœ ์ด๋ฃจ์–ด์ง„ homotrimer ๋˜๋Š” ์„œ๋กœ ๋‹ค๋ฅธ ์‚ฌ์Šฌ๋กœ ์ด๋ฃจ์–ด์ง„ heterotrimer ํ˜•ํƒœ๋กœ ์กด์žฌํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

Triple helix domain์˜ ์ค‘์‹ฌ๋ถ€์—๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์€ ํŠน์ง•์ ์ธ ๋ฐ˜๋ณต ์„œ์—ด์ด ์กด์žฌํ•ฉ๋‹ˆ๋‹ค.

Glyโ€“Xโ€“Y motif

  • Gly: glycine
  • X / Y: ์ฃผ๋กœ proline ๋˜๋Š” hydroxyproline

์ด๋Ÿฌํ•œ ๋ฐ˜๋ณต ๊ตฌ์กฐ๋Š” ์ฝœ๋ผ๊ฒ์˜ ์•ˆ์ •์ ์ธ triple helix ๊ตฌ์กฐ ํ˜•์„ฑ์— ํ•„์ˆ˜์ ์ž…๋‹ˆ๋‹ค.

ํ”„๋กœ์ฝœ๋ผ๊ฒ์€ ์ดํ›„ proteolytic cleavage๋ฅผ ํ†ตํ•ด N- ๋ฐ C-๋ง๋‹จ propeptide๊ฐ€ ์ œ๊ฑฐ๋˜๋ฉฐ, ๊ทธ ๊ฒฐ๊ณผ ์„ฑ์ˆ™ํ•œ ์ฝœ๋ผ๊ฒ ๋ถ„์ž(mature collagen molecules)๊ฐ€ ํ˜•์„ฑ๋ฉ๋‹ˆ๋‹ค.


Classical EDS ์›์ธ

Classical EDS๋Š” Type V collagen ๊ฒฐํ•จ์œผ๋กœ ๋ฐœ์ƒํ•ฉ๋‹ˆ๋‹ค.

Type V collagen์€ heterotrimer ๊ตฌ์กฐ๋กœ ์ด๋ฃจ์–ด์ ธ ์žˆ์œผ๋ฉฐ, ํ•˜๋‚˜์˜ heterotrimer๋Š” ๋‘ ๊ฐœ์˜ ฮฑ1(V) chain๊ณผ ํ•œ ๊ฐœ์˜ ฮฑ2(V) chain์œผ๋กœ ๊ตฌ์„ฑ๋ฉ๋‹ˆ๋‹ค.

์ด๋Ÿฌํ•œ ฮฑ-chain์„ ์•”ํ˜ธํ™”ํ•˜๋Š” ์œ ์ „์ž๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค.

  • ฮฑ1(V): COL5A1
  • ฮฑ2(V): COL5A2

โ†’ ์ฝœ๋ผ๊ฒ ์„ฌ์œ  ํ˜•์„ฑ(collagen fibrillogenesis)์— ํ•„์ˆ˜์ ์ธ ์—ญํ• ์„ ํ•ฉ๋‹ˆ๋‹ค.

1. COL5A1 ๋ณ€์ด ํŠน์ง•

๋Œ€๋ถ€๋ถ„ haploinsufficiency

์ฃผ์š” ๋ณ€์ด

  • nonsense
  • frameshift

์ด ๋ณ€์ด๋Š” NMD (nonsense mediated decay)๋ฅผ ์œ ๋ฐœํ•ฉ๋‹ˆ๋‹ค.

๊ฒฐ๊ณผ์ ์œผ๋กœ ์ •์ƒ collagen V ์ƒ์‚ฐ์ด ์•ฝ 50% ๊ฐ์†Œํ•ฉ๋‹ˆ๋‹ค.

2. COL5A2 ๋ณ€์ด ํŠน์ง•

COL5A2์—์„œ๋Š”

  • missense
  • in-frame indel

๊ฐ™์€ ๊ตฌ์กฐ์  ๋ณ€์ด๊ฐ€ ์ฃผ๋กœ ๋ฐœ๊ฒฌ๋ฉ๋‹ˆ๋‹ค.

์ด๋Ÿฌํ•œ ๋ณ€์ด๋Š” collagen ๊ตฌ์กฐ ์ž์ฒด๋ฅผ ์ง์ ‘ ์†์ƒ์‹œํ‚ค๊ธฐ ๋•Œ๋ฌธ์— ์ข…์ข… ๋” ์‹ฌํ•œ ์ž„์ƒ ํ‘œํ˜„ํ˜•์„ ์œ ๋ฐœํ•ฉ๋‹ˆ๋‹ค.


Vascular EDS ์›์ธ

Vascular EDS๋Š” COL3A1 ์œ ์ „์ž ๋ณ€์ด๋กœ ๋ฐœ์ƒํ•ฉ๋‹ˆ๋‹ค.
Type III collagen์€ homotrimer ๊ตฌ์กฐ๋ฅผ ๊ฐ€์ง€๋ฉฐ, ์„ธ ๊ฐœ์˜ ๋™์ผํ•œ ฮฑ1(III) chain์œผ๋กœ ๊ตฌ์„ฑ๋ฉ๋‹ˆ๋‹ค

  • collagen fibril assembly
  • fibril diameter ์กฐ์ ˆ

์— ์ค‘์š”ํ•œ ์—ญํ• ์„ ํ•ฉ๋‹ˆ๋‹ค.

๋Œ€ํ‘œ์ ์ธ ๋ณ‘๋ฆฌ ๊ธฐ์ „์€ ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค.

  • glycine substitution
  • in-frame indel

in the triple helical domain

์ด ๋ณ€์ด๋Š”

  • dominant negative collagen misfolding
  • ER retention
  • secretion failure

์„ ์œ ๋ฐœํ•ฉ๋‹ˆ๋‹ค.

๊ทธ ๊ฒฐ๊ณผ ECM ๊ตฌ์กฐ๊ฐ€ ์•ฝํ™”๋˜์–ด

  • ํ˜ˆ๊ด€ ํŒŒ์—ด
  • ์žฅ๊ธฐ ํŒŒ์—ด

๊ฐ™์€ ์‹ฌ๊ฐํ•œ ํ•ฉ๋ณ‘์ฆ์ด ๋ฐœ์ƒํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.


Type I collagen ๊ด€๋ จ EDS

Type I collagen์€ ECM์—์„œ ๊ฐ€์žฅ ํ’๋ถ€ํ•œ ๋‹จ๋ฐฑ์งˆ์ž…๋‹ˆ๋‹ค.
Type I collagen์€ heterotrimer ๊ตฌ์กฐ๋ฅผ ๊ฐ€์ง€๋ฉฐ, ๋‘ ๊ฐœ์˜ ฮฑ1(I) chain๊ณผ ํ•˜๋‚˜์˜ ฮฑ2(I) chain์œผ๋กœ ๊ตฌ์„ฑ๋ฉ๋‹ˆ๋‹ค.

๊ด€๋ จ ์œ ์ „์ž

  • COL1A1
  • COL1A2

๋Œ€๋ถ€๋ถ„์˜ ๋ณ€์ด๋Š” osteogenesis imperfecta๋ฅผ ์œ ๋ฐœํ•˜์ง€๋งŒ ์ผ๋ถ€๋Š” EDS subtype์„ ์œ ๋ฐœํ•ฉ๋‹ˆ๋‹ค. ์ฃผ์š” ๋ณ‘๋ฆฌ ๊ธฐ์ „์€ N-propeptide cleavage ๋ฐ procollagen processing ๊ณผ์ •์˜ ์ด์ƒ์œผ๋กœ ์ธํ•ด ์ •์ƒ์ ์ธ collagen fibrillogenesis๊ฐ€ ์ด๋ฃจ์–ด์ง€์ง€ ์•Š๋Š” ๊ฒƒ์ž…๋‹ˆ๋‹ค.

๋Œ€ํ‘œ์ ์ธ ์˜ˆ:

Arthrochalasia EDS (aEDS)

  • ์ดํ˜•์ ‘ํ•ฉ COL1A1 / COL1A2 ๋ณ€์ด
    (exon 6 ๋ถ€๋ถ„ ๋˜๋Š” ์ „์ฒด ๊ฒฐ์‹ค)
  • N-propeptide cleavage site ์†Œ์‹ค
  • Cross-linking lysine / protease cleavage site / ์ดˆ๊ธฐ triple-helix triplet ์†Œ์‹ค
  • Type I procollagen์˜ N-terminal์ด ์ œ๊ฑฐ๋˜์ง€ ์•Š๊ณ  ์ผ๋ถ€ ๋‚จ์Œ
  • Procollagen processing ์ด์ƒ ๋ฐœ์ƒ
    โ†’ Collagen fibrillogenesis ์žฅ์• 

ํŠน์ง•

  • ์‹ฌํ•œ ๊ด€์ ˆ ๊ณผ์šด๋™์„ฑ
  • ์„ ์ฒœ์„ฑ ๊ณ ๊ด€์ ˆ ํƒˆ๊ตฌ

Dermatosparaxis EDS (dEDS)

์›์ธ

ADAMTS2 ๋ณ€์ด/์–‘์ชฝ ๋Œ€๋ฆฝ์œ ์ „์ž ADAMTS2 ๊ธฐ๋Šฅ ์†Œ์‹ค (biallelic loss)
Procollagen N-cleavage ์‹คํŒจ
๋น„์ •์ƒ์ ์ธ ์ฝœ๋ผ๊ฒ ์„ฌ์œ  ํ˜•์„ฑ

ํŠน์ง•

  • extreme skin fragility
  • severe bruising

์ „์žํ˜„๋ฏธ๊ฒฝ์—์„œ hieroglyphic collagen fibril ํ˜•ํƒœ๊ฐ€ ๊ด€์ฐฐ๋ฉ๋‹ˆ๋‹ค.

aEDS์™€ dEDS์˜ ํ‘œํ˜„ํ˜• ์ฐจ์ด๋Š” protease redundancy์— ์˜ํ•ด ์„ค๋ช…๋ฉ๋‹ˆ๋‹ค.
(ADAMTS3,ADAMTS14 ๋“ฑ ๋‹ค๋ฅธ ํšจ์†Œ๊ฐ€ ์ผ๋ถ€ ๊ธฐ๋Šฅ์„ ๋ณด์™„)

๋˜ํ•œ ADAMTS2๋Š” ๋‹ค์–‘ํ•œ ๊ธฐ์งˆ(substrate)์„ ์ฒ˜๋ฆฌํ•˜๋Š” ํšจ์†Œ์ž…๋‹ˆ๋‹ค.
โ†’ ์ด๋Ÿฌํ•œ ์ฐจ์ด๊ฐ€ ์งˆํ™˜์˜ ํ‘œํ˜„ํ˜• ์ฐจ์ด์— ์˜ํ–ฅ์„ ๋ฏธ์นฉ๋‹ˆ๋‹ค.

Type I collagen ๊ด€๋ จ ๋‹ค๋ฅธ EDS ๊ธฐ์ „๋„ ์žˆ์Šต๋‹ˆ๋‹ค.

Cardiac valvular EDS (cvEDS)

  • biallelic COL1A2 loss-of-function ๋ณ€์ด
  • NMD์— ์˜ํ•ด mRNA ๋ถˆ์•ˆ์ • โ†’ proฮฑ2(I) chain ๊ฒฐํ•
  • ฮฑ1(I) homotrimer collagen ํ˜•์„ฑ
  • ์‹ฌํ•œ ๋‹คํŒ๋ง‰ ์‹ฌ์žฅ์งˆํ™˜ ๋ฐœ์ƒ

๋Œ€์กฐ๋˜๋Š” ๊ธฐ์ „

  • biallelic COL1A2 LoF์ด์ง€๋งŒ mRNA๊ฐ€ ์•ˆ์ •์ ์ธ ๊ฒฝ์šฐ
  • ๋ถˆ์•ˆ์ •ํ•œ ๋‹จ๋ฐฑ์งˆ โ†’ UPR (ER stress) ํ™œ์„ฑํ™”
  • ๊ฒฝ๋„โ€“์ค‘๋“ฑ๋„ Osteogenesis imperfecta ๋ฐœ์ƒ
    โ†’ ECM ์ด์ƒ vs ER stress ๊ธฐ๋ฐ˜ ๋ณ‘๋ฆฌ ๊ธฐ์ „ ์ฐจ์ด


COL1A1 Arg โ†’ Cys ๋ณ€์ด

  • ์ดํ˜•์ ‘ํ•ฉ COL1A1 Argโ†’Cys ์น˜ํ™˜ ๋ณ€์ด
  • Triple helix์— cysteine ๋„์ž… โ†’ ๋น„์ •์ƒ์ ์ธ disulfide-bond dimer ํ˜•์„ฑ
  • ๊ตญ์†Œ์ ์ธ collagen ๊ตฌ์กฐ ๋ถˆ์•ˆ์ • ๋ฐ ECM ์ƒํ˜ธ์ž‘์šฉ ๋ณ€ํ™”
  • vEDS์™€ ์œ ์‚ฌํ•œ ๋™๋งฅ ํŒŒ์—ด ์œ„ํ—˜ ยฑ cEDS ์œ ์‚ฌ ํ”ผ๋ถ€/๊ด€์ ˆ ์ฆ์ƒ

ํ‘œํ˜„ํ˜• ์ŠคํŽ™ํŠธ๋Ÿผ

  • ์ผ๋ถ€ ๋ณ€์ด โ†’ COL5 ๋ณ€์ด ์—†์ด cEDS ์œ ์‚ฌ ํ‘œํ˜„ํ˜•
  • ๋‹ค๋ฅธ ๋ณ€์ด โ†’ EDS / OI overlap (๊ด€์ ˆ ๊ณผ์ด์™„ + ๊ฒฝํ•œ ๊ณจ ์ทจ์•ฝ์„ฑ)


Collagen crosslinking ์ด์ƒ: kEDS

Collagen fibrillogenesis ๋‹จ๊ณ„๋ฟ ์•„๋‹ˆ๋ผ, collagen์˜ folding ๋ฐ cross-linking ๊ณผ์ •์— ์ด์ƒ์ด ๋ฐœ์ƒํ•ด๋„ EDS๊ฐ€ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ๊ฒฝ์šฐ ์ฃผ๋กœ kyphoscoliotic EDS ํ˜•ํƒœ๋กœ ๋ฐœํ˜„๋ฉ๋‹ˆ๋‹ค.

Kyphoscoliotic EDS (kEDS)

Kyphoscoliotic EDS๋Š” ๋‘ ๊ฐ€์ง€ ์œ ์ „์ž์—์„œ ๋ฐœ์ƒํ•ฉ๋‹ˆ๋‹ค.

PLOD1

lysyl hydroxylase ๊ฒฐํ• โ†’ collagen crosslinking ์žฅ์• 

์•ฝ 30%์˜ ๋ณ€์ด๋Š” exon 10โ€“16 ์ค‘๋ณต์œผ๋กœ ๋ฐœ์ƒํ•˜๋ฉฐ, ์ด๋Š” Alu-mediated recombination์— ์˜ํ•ด ๋ฐœ์ƒํ•ฉ๋‹ˆ๋‹ค.

์ž„์ƒ ํŠน์ง•

  • progressive scoliosis
  • vascular fragility

FKBP14

ER chaperone ๋‹จ๋ฐฑ์งˆ โ†’ collagen folding ์žฅ์• 

๊ฒฐ๊ณผ

  • ER collagen accumulation
  • abnormal fibril formation

Founder frameshift variant๊ฐ€ ๋Œ€๋ถ€๋ถ„์˜ alleles๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.


ECM ๊ตฌ์กฐ ๋‹จ๋ฐฑ์งˆ ๊ฒฐํ•จ

์ผ๋ถ€ EDS subtype์€ collagen ์ž์ฒด์˜ ์ด์ƒ์ด ์•„๋‹ˆ๋ผ, collagen ์ฃผ๋ณ€์˜ ๋‹ค๋ฅธ ECM organizing protein์˜ ์ด์ƒ์œผ๋กœ ๋ฐœ์ƒํ•ฉ๋‹ˆ๋‹ค

Classical-like EDS

์›์ธ

  • TNXB

์–‘์ชฝ ๋Œ€๋ฆฝ์œ ์ „์ž TNXB ๊ธฐ๋Šฅ์†Œ์‹ค ๋ณ€์ด (biallelic LoF)
โ†’ Tenascin-X ๊ฒฐํ• ๋ฐœ์ƒ

๊ฒฐ๊ณผ

  • collagen fibril organization ์žฅ์• 

์ฆ์ƒ

ํ”ผ๋ถ€ ๊ณผ์‹ ์ „์„ฑ (์œ„์ถ•์„ฑ ํ‰ํ„ฐ ์—†์Œ)

  • ๋ฉ์ด ์ž˜ ๋“ฆ, ๊ด€์ ˆ ๊ณผ์šด๋™์„ฑ ยฑ ๊ทผ๋ ฅ ์•ฝํ™”

์ดํ˜•์ ‘ํ•ฉ ๋ณด์ธ์ž (heterozygotes)

  • TNX ๊ฐ์†Œ
  • ์ผ๋ถ€์—์„œ ๊ด€์ ˆ ๊ณผ์šด๋™์„ฑ (๋“œ๋ฌผ๊ฒŒ hEDS์™€ ์—ฐ๊ด€ ๋ณด๊ณ )

Myopathic EDS

์›์ธ

  • COL12A1

์ดํ˜•์ ‘ํ•ฉ ๋˜๋Š” ์–‘์ชฝ ๋Œ€๋ฆฝ์œ ์ „์ž ๋ณ€์ด (COL12A1, type XII collagen)


ํŠน์ง•

  • EDS + ๊ทผ์œก๋ณ‘์ฆ

์–‘์ชฝ ๋Œ€๋ฆฝ์œ ์ „์ž ๋ณ€์ด(biallelic)์—์„œ๋Š” ์‹ฌํ•œ ์„ ์ฒœ์„ฑ ํ˜•ํƒœ๋กœ ๋‚˜ํƒ€๋‚˜๋ฉฐ, ์ดํ˜•์ ‘ํ•ฉ ๋ณ€์ด(heterozygous)์—์„œ๋Š” ๋ณด๋‹ค ๊ฒฝํ•œ ํ‘œํ˜„ํ˜•์œผ๋กœ ๋‚˜ํƒ€๋‚ฉ๋‹ˆ๋‹ค.


Glycosaminoglycan ํ•ฉ์„ฑ ์ด์ƒ

Proteoglycan์€

  • ECM ๊ตฌ์กฐ ์œ ์ง€
  • Collagen ๊ฐ„๊ฒฉ ์กฐ์ ˆ (collagen spacing)
  • Cell signaling ์กฐ์ ˆ

๋“ฑ ์—ฌ๋Ÿฌ ๊ณผ์ •์—์„œ ์ค‘์š”ํ•œ ์—ญํ• ์„ ํ•ฉ๋‹ˆ๋‹ค.

Proteoglycan์€ core protein๊ณผ GAG chains (HS, CS, DS)๋กœ ๊ตฌ์„ฑ๋˜์–ด ์žˆ์œผ๋ฉฐ, GAG chain ํ•ฉ์„ฑ ๊ณผ์ •์— ์ด์ƒ์ด ๋ฐœ์ƒํ•˜๋ฉด EDS๊ฐ€ ๋ฐœ์ƒํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

Spondylodysplastic EDS

์›์ธ

B4GALT7
B3GALT6

GAG chain ํ•ฉ์„ฑ์€ core protein์— tetrasaccharide linker๊ฐ€ ๋ถ€์ฐฉ๋˜๋Š” ๊ณผ์ •์—์„œ ์‹œ์ž‘๋ฉ๋‹ˆ๋‹ค. ์ด ๊ณผ์ •์—์„œ B4GALT7 ๋˜๋Š” B3GALT6 ๋ณ€์ด๊ฐ€ ๋ฐœ์ƒํ•˜๋ฉด linker์˜ galactosylation์— ๋ฌธ์ œ๊ฐ€ ์ƒ๊น๋‹ˆ๋‹ค.

๊ทธ ๊ฒฐ๊ณผ

  • core protein์— ๋‹น(sugar)์„ ์ •์ƒ์ ์œผ๋กœ ์ถ”๊ฐ€ํ•  ์ˆ˜ ์—†๊ฒŒ ๋˜๊ณ 
  • HS (heparan sulfate) ๋ฐ CS (chondroitin sulfate)๊ฐ€ ๊ฐ์†Œํ•˜๊ฑฐ๋‚˜ ์งง์•„์ง€๋ฉฐ
  • decorin์—์„œ DS (dermatan sulfate)๊ฐ€ ์†Œ์‹ค๋ฉ๋‹ˆ๋‹ค.

ํŠน์ง•

  • skeletal dysplasia
  • hypotonia

Musculocontractural EDS

์›์ธ

  • CHST14
  • DSE

CHST14 ๋˜๋Š” DSE ์œ ์ „์ž์— ์–‘์ชฝ ๋Œ€๋ฆฝ์œ ์ „์ž ๋ณ€์ด(biallelic variants)๊ฐ€ ๋ฐœ์ƒํ•˜๋ฉด DS(dermatan sulfate) ํ•ฉ์„ฑ์— ์žฅ์• ๊ฐ€ ์ƒ๊น๋‹ˆ๋‹ค. ์ด๋กœ ์ธํ•ด DS๊ฐ€ ๊ฐ์†Œํ•˜๊ฑฐ๋‚˜ ์†Œ์‹ค๋˜๋ฉฐ, ๊ทธ ์ž๋ฆฌ๋ฅผ CS(chondroitin sulfate)๊ฐ€ ๋Œ€์‹ ํ•˜๊ฒŒ ๋ฉ๋‹ˆ๋‹ค.
๊ทธ ๊ฒฐ๊ณผ decorin์˜ ์ •์ƒ์ ์ธ ๊ธฐ๋Šฅ์ด ์†์ƒ(dysfunction)๋˜์–ด ECM ๊ตฌ์กฐ์™€ collagen ์กฐ์งํ™”์— ๋ฌธ์ œ๊ฐ€ ๋ฐœ์ƒํ•ฉ๋‹ˆ๋‹ค.

ํŠน์ง•

  • congenital contracture
  • craniofacial anomalies


Other Intracellular Molecules ๊ฒฐํ•จ

spEDS (SLC39A13-related)

  • ์–‘์ชฝ ๋Œ€๋ฆฝ์œ ์ „์ž SLC39A13 ๋ณ€์ด
  • ZIP13 zinc transporter ๊ธฐ๋Šฅ ์ด์ƒ โ†’ ์„ธํฌ์งˆ๋กœ์˜ zinc ์œ ์ž… ๊ฐ์†Œ

๊ทธ ๊ฒฐ๊ณผ

  • Collagen lysyl / prolyl hydroxylation ๊ฐ์†Œ
    โ†’ ECM crosslinking ์ด์ƒ

์ถ”์ • ๊ธฐ์ „

  • Zn / Fe ๋ถˆ๊ท ํ˜•
  • lysyl hydroxylase, prolyl hydroxylase์™€ ๊ฒฝ์Ÿ์  ๊ฒฐํ•ฉ
  • ER stress
  • BMP / TGFฮฒ signaling ๋ณ€ํ™”

โ†’ ์ตœ์ข…์ ์œผ๋กœ collagen modification ์ด์ƒ๊ณผ ๊ฒฐํ•ฉ์กฐ์ง ์•ˆ์ •์„ฑ ์ €ํ•˜ ๋ฐœ์ƒ

Brittle Cornea Syndrome (BCS)

  • ์–‘์ชฝ ๋Œ€๋ฆฝ์œ ์ „์ž ZNF469 ๋˜๋Š” PRDM5 ๋ณ€์ด

์ฃผ์š” ํŠน์ง•

  • ๋งค์šฐ ์–‡๊ณ  ์ทจ์•ฝํ•œ ๊ฐ๋ง‰
    โ†’ ๊ฐ๋ง‰ ํŒŒ์—ด ์œ„ํ—˜ ์ฆ๊ฐ€

PRDM5 ๊ธฐ๋Šฅ

  • ECM ์œ ์ „์ž ๋ฐœํ˜„์„ ์กฐ์ ˆํ•˜๋Š” ์ „์‚ฌ ์กฐ์ ˆ ์ธ์ž

๊ทธ ๊ฒฐ๊ณผ

  • ECM ์œ ์ „์ž ๋ฐœํ˜„ ์ด์ƒ
    โ†’ collagen, fibronectin, integrin ์นจ์ฐฉ(deposition) ๋ณ€ํ™”


Complement pathway ๊ด€๋ จ EDS

Periodontal EDS

  • ์ดํ˜•์ ‘ํ•ฉ C1R ๋˜๋Š” C1S ๋ณ€์ด
    (classical complement pathway ๊ด€๋ จ ์œ ์ „์ž)

์ฃผ์š” ํŠน์ง•

  • ์‹ฌํ•œ ์น˜์ฃผ์—ผ (aggressive periodontitis)
  • ์กฐ๊ธฐ ์น˜์•„ ์ƒ์‹ค
  • ๊ฒฝํ•œ ๊ด€์ ˆ ๊ณผ์šด๋™์„ฑ

๋ณ‘๋ฆฌ ๊ธฐ์ „

  • C1 protease์˜ GoF ํ™œ์„ฑํ™”
    โ†’ ๊ตญ์†Œ์ ์ธ complement ํ™œ์„ฑ ์ฆ๊ฐ€

์ถ”์ • ๊ธฐ์ „

  • CUB domain์„ ํ†ตํ•œ ECM / collagen๊ณผ์˜ ๋น„์ •์ƒ์  ์ƒํ˜ธ์ž‘์šฉ
    โ†’ ๋ฉด์—ญ๊ณ„์™€ ๊ฒฐํ•ฉ์กฐ์ง ๊ฐ„ ์ƒํ˜ธ์ž‘์šฉ์˜ ์ค‘์š”์„ฑ ์‹œ์‚ฌ

Periodontal EDS

  • ์–‘์ชฝ ๋Œ€๋ฆฝ์œ ์ „์ž AEBP1 ๋ณ€์ด
    โ†’ ACLP (collagen-binding ECM protein) ์†Œ์‹ค

์ฃผ์š” ํŠน์ง•

  • ํ”ผ๋ถ€ ๊ณผ์‹ ์ „์„ฑ ๋ฐ ์œ„์ถ•์„ฑ ํ‰ํ„ฐ
  • ๊ด€์ ˆ ๊ณผ์šด๋™์„ฑ
  • ๊ณจ๊ฐ์†Œ์ฆ(osteopenia)

๋ณ‘๋ฆฌ ๊ธฐ์ „

  • Collagen I polymerization ์ด์ƒ

์ถ”์ • ๊ธฐ์ „

  • TGFฮฒ signaling ๋ณ€ํ™” (fibroblast ์ „ํ™˜ ์˜ํ–ฅ)
  • Wnt signaling ๋ณ€ํ™” (๊ณจ ํ•ญ์ƒ์„ฑ ์˜ํ–ฅ)

โ†’ ์ •ํ™•ํ•œ ๋ณ‘๋ฆฌ ๊ธฐ์ „์€ ์•„์ง ์™„์ „ํžˆ ๊ทœ๋ช…๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.


EDS ์ง„๋‹จ ๋ฐฉ๋ฒ•

EDS ์ง„๋‹จ ์‹œ ๋‹ค์Œ ํŠน์ง•๋“ค์„ ํ‰๊ฐ€ํ•ฉ๋‹ˆ๋‹ค.

๊ณตํ†ต ํŠน์ง•

  • generalized joint hypermobility
  • skin hyperextensibility
  • easy bruising
  • abnormal wound healing
  • tissue fragility

๋˜ํ•œ ๊ฐ€์กฑ๋ ฅ ํ‰๊ฐ€์™€ ์ „์‹ ์  ์ž„์ƒ ํ‰๊ฐ€๊ฐ€ ์ค‘์š”ํ•ฉ๋‹ˆ๋‹ค.


EDS ์ง„๋‹จ์ด ์–ด๋ ค์šด ์ด์œ 

EDS๋Š” ํŠนํžˆ ์†Œ์•„์—์„œ ์ง„๋‹จ์ด ๋Šฆ์–ด์ง€๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์Šต๋‹ˆ๋‹ค.

๊ทธ ์ด์œ ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค.

  • ์กฐ์ง ์ทจ์•ฝ์„ฑ์ด ์ •์ƒ ๋ฒ”์œ„๋กœ ์˜คํ•ด๋  ์ˆ˜ ์žˆ์Œ
  • ํ”ผ๋ถ€ ๊ณผ์‹ ์ „์ด ํ”ผํ•˜์ง€๋ฐฉ์— ์˜ํ•ด ๊ฐ€๋ ค์งˆ ์ˆ˜ ์žˆ์Œ
  • ๋ฉ์ด๋‚˜ ํ”ผ๋ถ€ ์†์ƒ์€ ๋ณดํ–‰ ์ดํ›„ ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์Œ

๋˜ํ•œ vEDS์˜ ํ˜ˆ๊ด€ ํŒŒ์—ด ๊ฐ™์€ ์‹ฌ๊ฐํ•œ ํ•ฉ๋ณ‘์ฆ์€ ๋Œ€๊ฐœ ์ฒญ์†Œ๋…„๊ธฐ ์ดํ›„ ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์Šต๋‹ˆ๋‹ค.



References

Malfait, F. et al. The Ehlersโ€“Danlos syndromes. Nat. Rev. Dis. Primers 6, 64 (2020).

Malfait, F. et al. The 2017 international classification of the Ehlersโ€“Danlos syndromes. Am. J. Med. Genet. C Semin. Med. Genet. 175, 8โ€“26 (2017).

Blackburn, P. R. et al. Bi-allelic alterations in AEBP1 lead to defective collagen assembly and connective tissue structure resulting in a variant of Ehlersโ€“Danlos syndrome. Am. J. Hum. Genet. 102, 696โ€“705 (2018).

Wenstrup, R. J. et al. What mouse mutants teach us about extracellular matrix function. Annu. Rev. Cell Dev. Biol. 22, 591โ€“621 (2006).

Gao, L., Orth, P., Cucchiarini, M. & Madry, H. Effects of solid acellular type-I/III collagen biomaterials on chondrogenesis of mesenchymal stem cells. Expert Rev. Med. Devices (2017).

Zhang, X. et al. Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes collagen cross-linking and ECM stiffening to induce liver fibrosis. Biochim. Biophys. Acta Mol. Basis Dis. 1870, 167205 (2024).

Lloyd, S. M. & He, Y. Exploring extracellular matrix crosslinking as a therapeutic approach to fibrosis. Cells 13, 438 (2024).

doi:10.3390/cells13050438

Ishikawa, Y. & Bรคchinger, H. P. A substrate preference for the rough endoplasmic reticulum resident protein FKBP22 during collagen biosynthesis. J. Biol. Chem. 289, 18189โ€“18201 (2014).

Lethias, C. et al.

A model of tenascin-X integration within the collagenous network.

FEBS Lett. 580, 6281โ€“6285 (2006)

Nguyen, M. & Panitch, A. Proteoglycans and proteoglycan mimetics for tissue engineering. Am. J. Physiol. Cell Physiol. 322, C754โ€“C761 (2022).

Ruiz Martรญnez, M. A., Peralta Galisteo, S., Castรกn, H. & Morales Hernรกndez, M. E. Role of proteoglycans on skin ageing: a review. Int. J. Cosmet. Sci. 42, 529โ€“535 (2020). 

Green, C. et al. Classical-like Ehlersโ€“Danlos syndrome: a clinical description of 20 newly identified individuals with evidence of tissue fragility. Genet. Med. 22, 1576โ€“1582 (2020).

Abdalla, E. M. et al. Kyphoscoliotic type of Ehlersโ€“Danlos syndrome (EDS VIA) in six Egyptian patients presenting with a homogeneous clinical phenotype. Eur. J. Pediatr. 174, 105โ€“112 (2015).

Chen, Y. et al. Role of genetics in amyotrophic lateral sclerosis: a large cohort study in Chinese mainland population. J. Med. Genet. 59, 840โ€“849 (2022).


์ฝ”๋ฉ˜ํŠธ

๋‹ต๊ธ€ ๋‚จ๊ธฐ๊ธฐ